Analysis
Superluminal Medicines, a Boston-based AI drug discovery startup, raised $60 million in a Series B round on September 3, with investors including BVF Partners, Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, Nvidia, Catalio Capital Management, Eli Lilly and Cooley, according to BioPharma Dive. The funds will support Phase 1 trials of an oral, selective MC4R agonist aimed initially at rare genetic and hypothalamic forms of obesity.
Founded in 2022, Superluminal uses machine learning to generate biomolecule structures and design small-molecule therapeutics de novo, with a focus on hard-to-drug GPCR targets in cardiometabolic disease. The company's approach already attracted a $1.3 billion collaboration deal with Eli Lilly -- which is also a Series B investor here -- to develop small-molecule therapeutics for cardiometabolic conditions more broadly.
Superluminal's MC4R candidate would compete in a category Rhythm Pharmaceuticals already commercialized with Imcivree for rare genetic obesity, and where Soleno Therapeutics (now under Neurocrine Biosciences) sells Vykat XR for Prader-Willi-associated hyperphagia. The bigger prize Superluminal is chasing is combination use alongside GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's own Zepbound, positioning MC4R agonism as an add-on rather than a standalone replacement in general obesity -- a market GLP-1s already dominate but haven't fully solved for patients who plateau or can't tolerate the side effects.
The obvious risk: MC4R-targeted obesity drugs have a mixed regulatory and commercial history, and an oral, AI-designed molecule still has to clear Phase 1 safety data before any of the platform's promise translates into a marketable product. Lilly's participation as both partner and investor gives Superluminal a distribution partner if the science holds, but also means Lilly captures much of the upside if it does. The obesity drug market itself remains dominated by GLP-1 injectables, but a growing body of clinical data suggests patients who plateau on semaglutide or tirzepatide need a mechanistically different add-on rather than a higher dose -- the gap Superluminal is explicitly designing for with an oral, non-injectable candidate that could lower the adherence barrier that limits GLP-1 uptake today.
